Evidence map›Paper›PMID 31662533›Full record

ArticleIn vivo (Athens, Greece)

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.

Annapaola Mariniello, Eleonora Ghisoni, Luisella Righi, Annamaria Catino, Rita Chiari, Alessandro Del Conte, Fausto Barbieri, Fabiana Cecere, Alain Gelibter, Matteo Giajlevra and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Annapaola MarinielloDepartment of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy.
Eleonora GhisoniDepartment of Oncology, University of Torino, Turin, Italy.
Luisella RighiDepartment of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy.
Annamaria CatinoThoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Rita ChiariDepartment of Medical Oncology, University of Perugia at Santa Maria della Misericordia Hospital, Perugia, Italy.
Alessandro Del ConteCentro di Riferimento Oncologico (CRO) - IRCCS, Oncology Unit, Pordenone, Italy.
Fausto BarbieriDepartment of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
Fabiana CecereCareggi University Hospital, Medical Oncology Unit, Department of Oncology, Florence, Italy.
Alain GelibterSapienza University of Rome at Policlinico Umberto I, Oncology Unit, Rome, Italy.
Matteo GiajlevraCHU Grenoble Alpes, Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Grenoble, France.
Hector Soto ParraAOU Policlinico Vittorio Emanuele, Medical Oncology, Catania, Italy.
Clizia ZichiDepartment of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy.
Massimo DI MaioDepartment of Oncology, University of Torino at Mauriziano Umberto I Hospital, Turin, Italy.
Giorgio ValabregaDepartment of Oncology, University of Torino, Turin, Italy giorgio.valabrega@unito.it.
Silvia NovelloDepartment of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimDouble diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns. PATIENTS AND

methodsClinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed.

resultsA total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months.

conclusionIn our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence.

Indexed as

AdenocarcinomaAdultAgedBRCA1 ProteinCarcinomaFemaleHumansLung NeoplasmsMiddle AgedMutationOvarian NeoplasmsPhthalazinesPiperazinesRetrospective StudiesBRCA1 ProteinolaparibPhthalazinesPiperazineshomologous recombination deficiencyimmunohistochemistryLung cancerovarian cancerwomen

Identifiers

PMID31662533
PMCPMC6899106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.